Latest News

Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.

Proactive management of EGFR-mediated toxicities can help to prevent the escalation of grade 1/2 skin toxicities to higher-grade events.

NCCN-indicated germline and somatic testing performance was inconsistent, although rates have been increasing due to concurrent quality improvement efforts.

Saum Ghodoussipour, MD, PhD, dissected the contrasting outcomes between adjuvant durvalumab plus tremelimumab compared with durvalumab alone in RCC.

Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.

Among patients treated in the PSMAtrack analysis, all had residual PSMA-avid disease following 6 months of systemic therapy for metastatic HPSC.

Retrospective data also showed that immune-related toxicities were more common with BCMA CAR T-cell therapy compared with teclistamab.

Giredestrant improved invasive disease–free survival vs endocrine therapy for patients with ER+, HER2– early breast cancer in the phase 3 lidERA trial.

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Leveraging 6-month PSA and PSMA-PET metrics may guide therapy escalation or de-escalation in metastatic hormone-sensitive prostate cancer.

Switching to camizestrant plus CDK4/6i upon ESR1 mutation detection demonstrated a PFS of 7.6 months and achieved significant PFS2 benefit in SERENA-6.

The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.

Grade 3 or higher TRAEs occurred in 73.7% of patients with HCC who received camrelizumab plus rivoceranib and TACE vs 28.7% who received TACE alone.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

Modulation of angiogenic and immune-related pathways in ccRCC might provide rationale for checkpoint- or VEGFR-TKI–based combinations with HC-7366.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Atebimetinib plus modified gemcitabine/nab-paclitaxel demonstrated an ORR of 36% and median OS of 17.3 months in first-line metastatic pancreatic cancer.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Fedratinib may target various proliferative pathways in MDS/MPN that other current standards of care miss, according to Andrew Kuykendall, MD.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.